Dr Pérol talks to ecancertv at ASCO 2014 about the findings from the REVEL phase III study of patients with stage IV non-small cell lung cancer (NSCLC), which indicate that a combination of a new anti-angiogenesis drug, ramucirumab, and standard docetaxel chemotherapy extends overall survival for patients who have a relapse after initial treatment, when compared to docetaxel plus placebo.